Geode Capital Management LLC Purchases 37,734 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Geode Capital Management LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,297,271 shares of the company's stock after purchasing an additional 37,734 shares during the period. Geode Capital Management LLC owned about 2.81% of IDEXX Laboratories worth $948,279,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at approximately $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $31,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $41,000. Finally, BankPlus Trust Department bought a new stake in IDEXX Laboratories during the 4th quarter worth $60,000. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Trading Down 2.8 %

IDXX stock traded down $10.99 during midday trading on Monday, hitting $382.74. The stock had a trading volume of 803,613 shares, compared to its average volume of 593,963. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market cap of $31.02 billion, a P/E ratio of 35.63, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The business has a fifty day moving average price of $435.55 and a two-hundred day moving average price of $439.31. IDEXX Laboratories, Inc. has a 1-year low of $365.93 and a 1-year high of $548.88.

Analyst Ratings Changes

Several equities analysts have commented on IDXX shares. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Bank of America raised their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday. Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.